Loomis, Sayles & Company
IRON icon

Loomis, Sayles & Company’s Disc Medicine IRON Stock Holding History

Loomis, Sayles & Company’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.9M Buy
381,864
+64,642
+20% +$4.44M 0.04% 196
2026
Q1 		$20.3M Buy
317,222
+34,813
+12% +$2.42M 0.03% 237
2025
Q4 		$22.4M Buy
+282,409
New +$23.9M 0.03% 221

Other funds holding IRON

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Loomis, Sayles & Company's IRON Position: Q2 2026 in Review

Loomis, Sayles & Company increased its Disc Medicine (IRON) stake by 20% in Q2 2026, buying an estimated $4.44M and bringing the position to 381,864 shares worth $27.9M. The position accounts for 0.04% of the portfolio, ranked #196.

Loomis, Sayles & Company first reported a position in IRON in Q4 2025 and has held it in 3 quarters since. 216 funds tracked by Wall St. Rank hold IRON as of Q2 2026.

  • Loomis, Sayles & Company held 381,864 shares of Disc Medicine worth $27.9M as of Q2 2026.
  • Loomis, Sayles & Company bought 64,642 Disc Medicine shares in Q2 2026, an estimated $4.44M.
  • Disc Medicine made up 0.04% of Loomis, Sayles & Company's portfolio in Q2 2026, its #196 holding.
  • Loomis, Sayles & Company first reported a position in Disc Medicine in Q4 2025 and has held it in 3 quarters since.
  • 216 funds tracked by Wall St. Rank held Disc Medicine as of Q2 2026.

Based on Loomis, Sayles & Company's 13F filing for Q2 2026, filed 14 Aug 2026.